Search PeptideClear
Peptides, vetted UK sellers, or GLP-1 clinics. Pick a tab below.
Try a quick search
We have not vetted that site yet.
PeptideClear can audit this source for you for free. Editorial verdict within 72 hours.
Got it. Editorial verdict within 72 hours.
We will email you a link to the published /retailer/[slug]/ profile once the audit lands.
While you wait, 3 already-vetted alternatives
Alternatives are matched to your stated goal. We earn nothing if you click through, and the links carry no tracking. How we are funded.
Regulatory tracker
Written and reviewed by the PeptideClear editorial team. · Best Business Loans Ltd (16833937)
Last updated:
The MHRA published 24 items in the 90 days to 2026-10-28, of which 1 relate to weight-loss medicines or peptides, 2 concern enforcement against illegal or unlicensed supply, and 4 are formal Drug Safety Updates. This page restates what the regulator published and links to each gov.uk original. It is a reporting record, not advice. If a medicine you take appears in a Drug Safety Update, the item itself tells you what the MHRA asks patients and prescribers to do, and your prescriber or pharmacist is the person to speak to.
24
MHRA items in the window
1
Relevant to this site
2
Enforcement actions
4
Drug Safety Updates
The subset that touches the categories this site covers. Everything else the regulator published in the same window is in the full table below.
Fake weight loss medicines worth approximately £2 million were seized last night in a raid executed by the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police.
Read the MHRA original on gov.ukEverything the MHRA published between 2026-09-02 and 2026-10-27, newest first. We list the full record rather than only the convenient parts, so the selection above can be checked against what was actually published.
| Date | Type | Item | Relevant to weight-loss medicines or peptides |
|---|---|---|---|
| 2026-10-27 | Announcement | New MHRA research puts needle-free Strep A vaccine within reach | No |
| 2026-10-26 | Drug safety update | #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app | No |
| 2026-10-23 | Announcement | MHRA approves new oral treatment for moderate to severe plaque psoriasis | No |
| 2026-10-23 | Announcement | MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults | No |
| 2026-10-21 | Announcement | Government confirms indefinite recognition of CE marked medical devices | No |
| 2026-10-20 | Drug safety update | IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review | No |
| 2026-10-19 | Announcement | MHRA consults on proposals to allow schools to keep spare adrenaline nasal sprays on site | No |
| 2026-10-19 | Announcement | UK regulator brings new AI and MedTech agenda to AdvaMed | No |
| 2026-10-19 | Announcement | MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome | No |
| 2026-10-15 | Drug safety update | Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction | No |
| 2026-10-15 | Announcement | MHRA introduces new safeguards to strengthen antidepressant safety information following major review | No |
| 2026-10-15 | Enforcement | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police | Yes |
| 2026-10-14 | Announcement | MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines | No |
| 2026-10-13 | Announcement | MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes | No |
| 2026-10-09 | Announcement | MHRA Chair Professor Anthony Harnden: Bringing our strategy to life – listening, learning, and looking ahead | No |
| 2026-10-07 | Announcement | MHRA approves catumaxomab to treat cancer-related fluid build-up in the abdomen | No |
| 2026-10-06 | Announcement | Government backs recommendations of NHS doctors-led AI Commission | No |
| 2026-10-01 | Announcement | MHRA joins global regulators in call to advance alternatives to animal testing | No |
| 2026-09-30 | Announcement | DIA and MHRA announce speaker line-up for inaugural global summit | No |
| 2026-09-24 | Enforcement | MHRA welcomes sentencing after fraud convictions over falsely certified medical devices | No |
| 2026-09-24 | Announcement | Five new commissioners appointed to the Commission on Human Medicines (CHM) | No |
| 2026-09-24 | Announcement | Professor Dame Anna Dominiczak, Professor Alison Strath, and Fiona Cochrane: Catalysing the medicines ecosystem in Scotland | No |
| 2026-09-23 | Announcement | MHRA approves lurbinectedin for adults with extensive-stage small cell lung cancer | No |
| 2026-09-02 | Drug safety update | Filters should be used during the administration of Parenteral Nutrition for patients in all care settings | No |
Source: gov.uk MHRA announcements feed and MHRA Drug Safety Update feed
### MHRA items published in the 90 days to 2026-10-28, by date and type | Date | Type | Item | Relevant to weight-loss medicines or peptides | | --- | --- | --- | --- | | 2026-10-27 | Announcement | New MHRA research puts needle-free Strep A vaccine within reach | No | | 2026-10-26 | Drug safety update | #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app | No | | 2026-10-23 | Announcement | MHRA approves new oral treatment for moderate to severe plaque psoriasis | No | | 2026-10-23 | Announcement | MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults | No | | 2026-10-21 | Announcement | Government confirms indefinite recognition of CE marked medical devices | No | | 2026-10-20 | Drug safety update | IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review | No | | 2026-10-19 | Announcement | MHRA consults on proposals to allow schools to keep spare adrenaline nasal sprays on site | No | | 2026-10-19 | Announcement | UK regulator brings new AI and MedTech agenda to AdvaMed | No | | 2026-10-19 | Announcement | MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome | No | | 2026-10-15 | Drug safety update | Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction | No | | 2026-10-15 | Announcement | MHRA introduces new safeguards to strengthen antidepressant safety information following major review | No | | 2026-10-15 | Enforcement | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police | Yes | | 2026-10-14 | Announcement | MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines | No | | 2026-10-13 | Announcement | MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes | No | | 2026-10-09 | Announcement | MHRA Chair Professor Anthony Harnden: Bringing our strategy to life – listening, learning, and looking ahead | No | | 2026-10-07 | Announcement | MHRA approves catumaxomab to treat cancer-related fluid build-up in the abdomen | No | | 2026-10-06 | Announcement | Government backs recommendations of NHS doctors-led AI Commission | No | | 2026-10-01 | Announcement | MHRA joins global regulators in call to advance alternatives to animal testing | No | | 2026-09-30 | Announcement | DIA and MHRA announce speaker line-up for inaugural global summit | No | | 2026-09-24 | Enforcement | MHRA welcomes sentencing after fraud convictions over falsely certified medical devices | No | | 2026-09-24 | Announcement | Five new commissioners appointed to the Commission on Human Medicines (CHM) | No | | 2026-09-24 | Announcement | Professor Dame Anna Dominiczak, Professor Alison Strath, and Fiona Cochrane: Catalysing the medicines ecosystem in Scotland | No | | 2026-09-23 | Announcement | MHRA approves lurbinectedin for adults with extensive-stage small cell lung cancer | No | | 2026-09-02 | Drug safety update | Filters should be used during the administration of Parenteral Nutrition for patients in all care settings | No | Source: gov.uk MHRA announcements feed and MHRA Drug Safety Update feed
“A rolling window is honest but it is not history. Items drop off this page after ninety days, so an absence here means the MHRA has not published on it recently, not that nothing has ever been published. Read the enforcement rows as evidence that illegal supply is actively prosecuted in the UK, and read a quiet period as ordinary rather than as reassurance about any particular seller.”
Last fetched 2026-10-28. PeptideClear is editorial. We do not prescribe, dispense or sell medicines.
PeptideClear is editorial. Nothing here replaces the regulator, and you should not take our word for any of it. These are the official UK destinations where the underlying position is published, free to read and open to anyone.
MHRA
MHRA Products portalThe Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
MHRA
Drug Safety UpdateThe MHRA monthly bulletin of safety advice for prescribers and patients. Where new risks and product information changes are formally announced.
MHRA
Report a fake or illegally supplied medicineThe MHRA route for reporting a website or seller supplying medicines illegally, and for reporting a product you believe is counterfeit.
Advertising Standards Authority
CAP Code and ASA rulingsThe UK advertising rules, including the ban on advertising prescription-only medicines to the public, and the published rulings that show how they are applied.
World Anti-Doping Agency
WADA Prohibited ListThe annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
legislation.gov.uk
Human Medicines Regulations 2012The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.
PeptideClear maintains these as refreshable datasets rather than one-off articles. Each carries its own source, methodology and last-updated date.
Live data tracker
UK GLP-1 prescribing tracker →
Monthly NHS England primary-care prescribing volumes for GLP-1 medications, rebuilt as each new month publishes. Dated chart, month-by-month table, full methodology.
Source: NHSBSA English Prescribing Dataset
Live data tracker
UK peptide clinical-trials tracker →
Registered interventional trials for every research peptide we track, by phase and recruitment status, linking through to each compound record.
Source: ClinicalTrials.gov and ISRCTN
Live data tracker
UK peptide regulation: monthly overview →
A monthly record combining the MHRA feed with a web-search pass for ASA rulings, Trading Standards action and named-retailer enforcement, each item linked to its source.
Source: gov.uk / MHRA / ASA / Trading Standards
Live data tracker
UK research-peptide price index →
Headline price per milligram across the UK research-peptide retailers we score, so a price can be read against the market rather than in isolation.
Source: PeptideClear retailer survey
Live data tracker
PeptideClear Trust Index →
156 UK sellers assessed for free across three baseline measures (Testing Transparency, Business Transparency, Responsible Practice), independently, on the Which? / Defaqto model. Testing Transparency alone draws on six observable certificate-of-analysis signals, reproducible from the published data.
Source: PeptideClear methodology
Live data tracker
Data API and MCP server →
Read-only, no-auth REST API and MCP server over the full scored dataset: corporate identity, regulatory status, CoA verification signals. CC BY 4.0.
Source: PeptideClear, live data
PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). PeptideClear's editorial and publishing operation is delivered by Best Business Loans Ltd.
Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates. Registered office: Cust Hall, Toppesfield, Halstead, Essex, CO9 4EB. Contact: [email protected].
Operates under UK data protection and consumer standards, including UK GDPR.
Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.